Regulatory T cells for transplant tolerance
The so-called natural CD4 +
CD25
+ regulatory T cells (Tregs) are thymus-derived suppressor cells that were first characterized in the landmark paper by Shimon Sakaguchi and colleagues as an anergic and suppressive T cell population that potently inhibits autoimmunity (1) . The later discovery that FOXP3 expression determines the thymic development and peripheral function of Tregs (2) justified the designation of this population as a separate T cell lineage and sparked the interest of the scientific community in Treg biology. Once it was shown that lack-of-function mutations of the FOXP3-encoding gene impair Treg function and cause severe and frequently lethal autoimmunity in mice and humans (scurfy and immune dysregulation, polyendocrinopathy, enteropathy, X-linked [IPEX] , respectively) (3, 4) , it was broadly recognized that Treg-mediated suppression plays a pivotal role in the maintenance of peripheral tolerance. These findings also illustrated that no other regulatory cell population compensates for the lack of FOXP3 + suppressor cells in the periphery. Tregs gain suppressive activity only after stimulation of their own T cell receptor; however, once activated, Tregs suppress effector T cells in their vicinity in a nonspecific manner (referred to as bystander or linked suppression). Initially, it was thought that Tregs employ a unique and Treg-specific mode of suppression, but it now seems that these cells apply various and variable suppressive mechanisms in response to the inflammatory microenvironment (5) . Furthermore, Tregs do not solely act on effector T cells, but modulate the function of virtually every cell type of the innate and adaptive immune system and even act on nonhematopoietic targets (6) .
The ability of Tregs to suppress T cell responses without mediating proinflammatory effects themselves has evoked the interest of transplantation immunologists, as such a cell population may dampen alloresponses without causing tissue damage. In murine disease models, it was shown that the adoptive transfer of donor Tregs prevents severe graft-versus-host disease (GVHD) after allogeneic stem cell transplantation (SCT), which otherwise would be initiated by conventional donor T cells contained in the stem cell graft (7) (8) (9) . Similarly, host-derived Tregs responding to donor alloantigens have been shown to ameliorate graft rejection after solid organ transplantation, suggesting that strengthening Tregmediated suppression may be an attractive strategy for promoting transplantation tolerance (10, 11) . Indeed, early clinical trials confirmed the suppressive activity of donor Tregs in SCT, as acute GVHD was prevented in individuals that received haploidentical grafts in the absence of pharmacologic immunosuppression (12) .
Applying CAR technology to Tregs
Second-generation chimeric antigen receptors (CARs), composed of single-chain variable fragments from an antibody fused to costimulatory and TCR signaling endodomains, trigger T cell responses in an HLAindependent manner upon CAR engagement. CD19-targeted CAR-T cells mediate potent cytotoxicity against malignant (as well as normal) B cells and induce complete remissions in patients with refractory acute lymphoblastic leukemia and certain lymphomas with unprecedented efficacy (13) (14) (15) . This groundbreaking progress has + Tregs maintain all the phenotypic and functional characteristics of thymic Tregs after isolation and extended in vitro expansion. Moreover, such cell products increased the Treg pool of several patients treated for refractory acute GVHD within an ongoing clinical trial at our institution (EudraCT 2012-002685-12). Redirecting Tregs toward a single HLA mismatch by CARs is a promising next step in the exploration of Treg-mediated suppression of alloresponses because bystander suppression may be sufficient to prevent (and eventually suppress an ongoing) polyclonal T cell response after HLA-mismatched stem cell or solid organ transplantanot for the long term. Hence, such models can be confirmative at most (in cases where the expected results are observed), but are unsuited to study the basic biology of human Tregs in vivo. The same considerations also apply to safety aspects of CARmodified Treg therapy that were addressed by MacDonald et al. in supplemental experiments in which HLA-A2-transgenic NSG mice were used as hosts. The lack of tissue damage after transfer of A2-CAR Tregs is reassuring, yet it should be noted that these immunodeficient xenogenic recipients lack pivotal cells and effector mechanisms/molecules that may indirectly contribute to tissue damage upon recognition of HLA-A2 on target organs by CAR-modified Tregs. Despite these reservations, the use of CARmodified Tregs is an attractive new strategy for enhancing transplantation tolerance in the future, and these Tregs are well worth examining in more detail in appropriate experimental models in preparation for first clinical trials. Several issues, including the selection of the CAR target antigens, remain to be addressed in more pertinent models. Tregs are CD4 + T cells that are usually restricted by HLA class II molecules. In murine models, the lymph node-homing capacity of donor Tregs is required for protection from acute GVHD, suggesting that class II-positive professional antigenpresenting cells (APCs) stimulate alloreactive Tregs and license them for the suppression of alloreactive effector T cells in lymphoid organs (21). Yet for therapeutic purposes, it may be that Treg-mediated suppression is primarily required in target organs and that activation via locally expressed HLA class I molecules is beneficial. However, the ubiquitous expression of class I molecules increases the risk of generalized immunosuppression by class I-targeted CAR-expressing Tregs and therefore might be detrimental for SCT patients with residual leukemia or lymphoma who rely on efficient graft-versus-leukemia effects and are prone to opportunistic infections. The incorporation of suicide genes or molecular on/off switches into CAR-expressing Tregs could enhance the safety profile of such suppressor cell products (22).
Clinical translation
The main hurdles for the clinical translation of experimental Treg therapies have been the paucity of thymus-derived inspired scientists, as well as biotech and pharmaceutical companies, to extend CAR-T cell therapy to other malignant diseases (16). An obvious next step in the exploitation of CAR technologies is the genetic modification of Tregs for the treatment of autoimmune diseases and for the induction of tolerance after allogeneic SCT or solid organ transplantation (17). Initial proof-ofconcept studies have already shown that CAR-redirected Tregs ameliorate experimental colitis (18) and that CAR-modified human Tregs gain suppressive activity upon antigen-specific CAR engagement (19). In this issue, MacDonald and colleagues report on the transduction of human Tregs with a CAR directed against the HLA class I molecule A2 to explore the capacity of these engineered cells to suppress alloresponses in vitro and in xenogenic models in vivo ( Cotransfer of anti-A2-CAR-modified Tregs ameliorated the development of lethal GVHD in this model, while cotransfer of Tregs expressing a HER2-specific control CAR did not improve outcome. Moreover, immune-monitoring data suggest that the observed delay in disease onset is caused by the Treg-mediated inhibition of effector T cell engraftment and expansion. Even though this kind of experiment is often performed (and frequently requested by reviewers) to illustrate human Treg efficacy for the prevention of GVHD, results should be interpreted with caution, as the xenogenic disease has hardly anything in common with human GVHD or GVHD in allogeneic transplant models. Furthermore, human Tregs do not survive in such hosts for more than a few days and thus can only act during the disease initiation phase, but 
